To develop a CRISPR-based method for in vivo production of CAR T cells, addressing significant manufacturing bottlenecks in cell therapy.
Key Findings:
Generated CAR T cells directly in vivo, reaching therapeutic levels.
Triggered expected biological effects, including B cell depletion.
Showed strong proliferation and anti-tumor activity in leukemia, myeloma, and solid tumor models.
Interpretation:
The CRISPR-based approach offers a promising alternative to conventional CAR T cell manufacturing, potentially reducing costs and significantly improving access to therapies.
Limitations:
Translation to human applications remains to be validated through clinical trials.
Long-term safety and efficacy in humans are not yet established.
Conclusion:
This innovative method could revolutionize CAR T cell therapy by simplifying production and enhancing accessibility.
